Serum Scores A Double - HPV Vaccine In India, Novavax Vaccine In US

Demand High For HPV, Low For COVID-19 Vaccine

Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.

Victory
Serum Institute Will Benefit From Twin Approvals • Source: Shutterstock

Sometimes timing is everything. Novavax, Inc. would be realizing that, given its COVID-19 vaccine has only recently secured an emergency use authorization (EUA) in the US, despite having an early start to its development program for NVX-CoV2373.

While mRNA rivals Pfizer Inc./BioNTech SE and Moderna, Inc. whizzed past in 2020, Novavax faced manufacturing troubles...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip